Chemotherapy News and Research

Latest Chemotherapy News and Research

Scientists discover structure of a protein that makes cancer cells resistant to chemotherapy

A research team at the Scripps Research Institute has obtained the first glimpse of a protein that keeps certain substances, including many drugs, out of cells.

29 Mar 2009

Twin nanoparticle shown effective at targeting, killing breast cancer cells

A team of investigators at Brown University has developed a novel way to treat a class of breast cancer cells. The team has created twin nanoparticles that specifically targets the Her-2 tumor cell and unload a cancer-fighting drug directly into it. The result is a boost in antitumor activity while minimizing side effects. The findings of this study have been published in the Journal of the American Chemical Society.

26 Mar 2009

Researchers decipher blood stem cell attachment, communication

Researchers at the National Institutes of Health have deciphered a key sequence of events governing whether the stem cells that produce red and white blood cells remain anchored to the bone marrow, or migrate into the circulatory system.

25 Mar 2009

Rexahn Pharmaceuticals starts phase II pancreatic cancer trial

Rexahn Pharmaceuticals, Inc. has announced that it has received FDA approval to begin Phase II trials for Archexin, the Company's leading cancer compound, for the treatment of pancreatic cancer.

24 Mar 2009

New test for breast cancer metastasis

Scientists at Albert Einstein College of Medicine of Yeshiva University have previously shown that the co-mingling of three cell types can predict whether localized breast cancer will spread throughout the body.

24 Mar 2009

Carnitine supplementation appears to prevent development of liver cancer

A study will be published on March 21, 2009 in World Journal of Gastroenterology addresses the question.

24 Mar 2009

3-drug chemotherapy combo increases organ preservation in patients with larynx cancer

Patients with larynx cancer who received a three-drug combination of docetaxel, cisplatin and 5-fluorouracil (TPF) during induction chemotherapy were more likely to retain larynx function than were patients treated with cisplatin and 5-fluoruracil (PF) alone, according to data from a randomized controlled trial in the March 24 online issue of the Journal of the National Cancer Institute.

24 Mar 2009

Study finds biological clue in brain tumor development

Scientists at The University of Nottingham have uncovered a vital new biological clue that could lead to more effective treatments for a children's brain tumour that currently kills more than 60 per cent of young sufferers.

20 Mar 2009

Scientists trial device to treat chemotherapy-related nausea

Trials to test acupressure wrist bands as a drug-free alternative for chemotherapy-related nausea are to take place at the University of Liverpool.

20 Mar 2009

Discovery of genetic markers for aggressive head and neck cancer

Scientists at Albert Einstein College of Medicine of Yeshiva University have identified genetic markers that signal poor outcomes for patients with head and neck cancer.

20 Mar 2009

Discovery of new protein important in breast cancer gene's role in DNA repair

For years, researchers have known that under normal conditions, the breast cancer protein BRCA1 orchestrates the repair of damaged DNA, but the details of just how BRCA1 moves to the damaged site and recruits the right nuclear repairmen for DNA restoration remains a mystery.

20 Mar 2009

Gleevec reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors

Data published online and in an upcoming print issue of The Lancet show that Gleevec (imatinib mesylate) tablets, when taken after surgery, substantially reduces the rate of recurrence of Kit-positive gastrointestinal stromal tumors (GIST) compared with placebo.

20 Mar 2009

New tumor markers determine therapy intensity

Characteristic changes in the DNA of medulloblastoma, the most frequent malignant brain tumor in childhood, indicate precisely how aggressively the tumor will continue to spread and what the chances of disease relapse are.

17 Mar 2009

Updated guidelines for ovarian cancer

Improvements in screening and early detection remains the key for women with ovarian cancer according to Robert J. Morgan, MD, of City of Hope Comprehensive Cancer Center and chair of the NCCN Guidelines Panel for Ovarian Cancer.

16 Mar 2009

Colon cancer screenings recommended at 45 for African Americans

According to the American Cancer Society, there were about 108,070 new cases of colon cancer and 40,740 new cases of rectal cancer in 2008. Overall, the two cancers caused nearly 50,000 deaths last year.

16 Mar 2009

Blocking the dual leucine zipper kinase gene may help ease painful nerve condition

Scientists have identified the first gene that pulls the plug on ailing nerve cell branches from within the nerve cell, possibly helping to trigger the painful condition known as neuropathy.

15 Mar 2009

Biothera receives approval to launch two lung cancer trials

German regulatory authorities have granted approval to Biothera to conduct two open label, multicenter, randomized Phase II clinical trials studying Imprime PGGÂ® administered in combination with monoclonal antibodies and chemotherapy in patients with non-small cell lung cancer (NSCLC), the company announced today.

12 Mar 2009

Oncolytics Biotech (TSX:ONC, NASDAQ:ONCY) starts U.S. enrolment in trial for non-small cell lung cancer patients

Oncolytics Biotech Inc. has announced that it has started patient enrolment in a Phase 2 clinical trial using intravenous administration of Reolysin in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with K-RAS or EGFR-activated tumours.

12 Mar 2009

Rituximab may be effective in treating membranous nephropathy

Current treatments for membranous nephropathy are limited to steroids, calcineurin inhibitors, and chemotherapeutic agents, all of which have significant side effects.

11 Mar 2009

Study of Rituxan (rituximab) in lupus nephritis misses primary endpoint

Genentech, Inc. and Biogen Idec has announced that a Phase III study of Rituxan (rituximab) plus mycophenolate mofetil (MMF) and corticosteroids in patients with lupus nephritis did not meet its primary endpoint of significantly reducing disease activity at 52 weeks.

11 Mar 2009